As the most widely used biologics in clinical practice, anti-TNF drugs not only reduced the risk of colorectal cancer in patients with IBD but also reduced the risk of colorectal cancer in patients with rheumatoid arthritis (with an adjusted hazard ratio of 0.51) (Mercer et al., 2015). This evidence concerns the gene TNF and rheumatoid arthritis.